雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Medical Therapeutic Strategy in Intestinal Lymphoma Michinori Ogura 1 1Department of Hematology, Nagoya Daini Red Cross Hospital Keyword: 腸管リンパ腫 , 腸管原発中悪性度非Hodgkinリンパ腫 , 腸管原発びまん性大細胞型B細胞性リンパ腫 , 腸管原発濾胞性リンパ腫 , CHOP療法 , R-CHOP療法 pp.338-344
Published Date 2006/3/25
DOI https://doi.org/10.11477/mf.1403100289
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 Primary gastrointestinal lymphomas constitute 5 to 10% of all gastrointestinal tumors. 20 to 30% of gastrointestinal lymphomas, or approximately 5% of non-Hodgkin's lymphomas (NHL) are, in general, primarily located in the intestine. 60 to 80% of intestinal lymphomas are B-cell lymphomas, mostly diffuse large B-cell lymphomas (DLBCL) of the distal small intestine and especially in the ileocecal region. Standard care for intestinal aggressive NHL (DLBCL) is 3 to 4 courses of CHOP[rituximab (R)-CHOP for DLBCL]after localized tumor resection followed by involved field radiotherapy (IFRT), or 6 courses of CHOP (R-CHOP for DLBCL) after localized tumor resection for the localized stage, and 8 courses of CHOP (R-CHOP for DLBCL) after localized tumor resection for the advanced stage. Primary gastrointestinal follicular lymphoma (FL) is a lymphoma, predominantly found in females, that most frequently involves the small intestine. The course of the disease is indolent and does not differ from nodal FL. Localized intestinal FL may be treated by IFRT or rituximab monotherapy. Semi-standard care for advanced intestinal FL is R-chemotherapy (e. g. R-CHOP) that is identical to the therapy for nodal FL.


Copyright © 2006, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院

関連文献

もっと見る

文献を共有